A preliminary study of intravenous surfactants in paraplegic dogs

Polymer therapy in canine clinical SCI

Peter H. Laverty, Alenka Leskovar, Gert J. Breur, Joan R. Coates, Robert L. Bergman, William R. Widmer, James P. Toombs, Scott Shapiro, Richard B. Borgens

Research output: Contribution to journalArticle

91 Citations (Scopus)

Abstract

Hydrophilic polymers, both surfactants and tri-block polymers, are known to seal defects in cell membranes. In previous experiments using laboratory animals, we have exploited this capability using polyethylene glycol (PEG) to repair spinal axons after severe, standardized spinal cord injury (SCI) in guinea pigs. Similar studies were conducted using a related co-polymer Poloxamer 188 (P 188). Here we carried out initial investigations of an intravenous application of PEG or P 188 (3500 Daltons, 30% w/w in saline; 2 mL/kg I.V. and 2 mL/kg body weight or 300 mL P 188 per kg, respectively) to neurologically complete cases of paraplegia in dogs. Our aim was to first determine if this is a clinically safe procedure in cases of severe naturally occurring SCI in dogs. Secondarily, we wanted to obtain preliminary evidence if this therapy could be of clinical benefit when compared to a larger number of similar, but historical, control cases. Strict entry criteria permitted recruitment of only neurologically complete paraplegic dogs into this study. Animals were treated by a combination of conventional and experimental techniques within ∼72 h of admission for spinal trauma secondary to acute, explosive disk herniation. Outcome measures consisted of measurements of voluntary ambulation, deep and superficial pain perception, conscious proprioception in hindlimbs, and evoked potentials (somatosensory evoked potentials [SSEP]). We determined that polymer injection is a safe adjunct to the conventional management of severe neurological injury in dogs. We did not observe any unacceptable clinical response to polymer injection; there were no deaths, nor any other problem arising from, or associated with, the procedures. Outcome measures over the 6-8-week trial were improved by polymer injection when compared to historical cases. This recovery was unexpectedly rapid compared to these comparator groups. The results of this pilot trial provides evidence consistent with the notion that the injection of inorganic polymers in acute neurotrauma may be a simple and useful intervention during the acute phase of the injury.

Original languageEnglish
Pages (from-to)1767-1777
Number of pages11
JournalJournal of Neurotrauma
Volume21
Issue number12
DOIs
StatePublished - Dec 2004

Fingerprint

Spinal Cord Injuries
Surface-Active Agents
Canidae
Polymers
Dogs
Injections
Therapeutics
Outcome Assessment (Health Care)
Poloxamer
Proprioception
Pain Perception
Somatosensory Evoked Potentials
Paraplegia
Wounds and Injuries
Laboratory Animals
Hindlimb
Evoked Potentials
Walking
Axons
Guinea Pigs

Keywords

  • Canine paraplegia
  • P 188
  • Paraplegia
  • Polyethylene glycol
  • Polymer
  • Spinal cord injury
  • Surfactant

ASJC Scopus subject areas

  • Clinical Neurology
  • Neuroscience(all)

Cite this

Laverty, P. H., Leskovar, A., Breur, G. J., Coates, J. R., Bergman, R. L., Widmer, W. R., ... Borgens, R. B. (2004). A preliminary study of intravenous surfactants in paraplegic dogs: Polymer therapy in canine clinical SCI. Journal of Neurotrauma, 21(12), 1767-1777. https://doi.org/10.1089/neu.2004.21.1767

A preliminary study of intravenous surfactants in paraplegic dogs : Polymer therapy in canine clinical SCI. / Laverty, Peter H.; Leskovar, Alenka; Breur, Gert J.; Coates, Joan R.; Bergman, Robert L.; Widmer, William R.; Toombs, James P.; Shapiro, Scott; Borgens, Richard B.

In: Journal of Neurotrauma, Vol. 21, No. 12, 12.2004, p. 1767-1777.

Research output: Contribution to journalArticle

Laverty, PH, Leskovar, A, Breur, GJ, Coates, JR, Bergman, RL, Widmer, WR, Toombs, JP, Shapiro, S & Borgens, RB 2004, 'A preliminary study of intravenous surfactants in paraplegic dogs: Polymer therapy in canine clinical SCI', Journal of Neurotrauma, vol. 21, no. 12, pp. 1767-1777. https://doi.org/10.1089/neu.2004.21.1767
Laverty, Peter H. ; Leskovar, Alenka ; Breur, Gert J. ; Coates, Joan R. ; Bergman, Robert L. ; Widmer, William R. ; Toombs, James P. ; Shapiro, Scott ; Borgens, Richard B. / A preliminary study of intravenous surfactants in paraplegic dogs : Polymer therapy in canine clinical SCI. In: Journal of Neurotrauma. 2004 ; Vol. 21, No. 12. pp. 1767-1777.
@article{ff0229cc64cd455c83e1eeff7ae6c27b,
title = "A preliminary study of intravenous surfactants in paraplegic dogs: Polymer therapy in canine clinical SCI",
abstract = "Hydrophilic polymers, both surfactants and tri-block polymers, are known to seal defects in cell membranes. In previous experiments using laboratory animals, we have exploited this capability using polyethylene glycol (PEG) to repair spinal axons after severe, standardized spinal cord injury (SCI) in guinea pigs. Similar studies were conducted using a related co-polymer Poloxamer 188 (P 188). Here we carried out initial investigations of an intravenous application of PEG or P 188 (3500 Daltons, 30{\%} w/w in saline; 2 mL/kg I.V. and 2 mL/kg body weight or 300 mL P 188 per kg, respectively) to neurologically complete cases of paraplegia in dogs. Our aim was to first determine if this is a clinically safe procedure in cases of severe naturally occurring SCI in dogs. Secondarily, we wanted to obtain preliminary evidence if this therapy could be of clinical benefit when compared to a larger number of similar, but historical, control cases. Strict entry criteria permitted recruitment of only neurologically complete paraplegic dogs into this study. Animals were treated by a combination of conventional and experimental techniques within ∼72 h of admission for spinal trauma secondary to acute, explosive disk herniation. Outcome measures consisted of measurements of voluntary ambulation, deep and superficial pain perception, conscious proprioception in hindlimbs, and evoked potentials (somatosensory evoked potentials [SSEP]). We determined that polymer injection is a safe adjunct to the conventional management of severe neurological injury in dogs. We did not observe any unacceptable clinical response to polymer injection; there were no deaths, nor any other problem arising from, or associated with, the procedures. Outcome measures over the 6-8-week trial were improved by polymer injection when compared to historical cases. This recovery was unexpectedly rapid compared to these comparator groups. The results of this pilot trial provides evidence consistent with the notion that the injection of inorganic polymers in acute neurotrauma may be a simple and useful intervention during the acute phase of the injury.",
keywords = "Canine paraplegia, P 188, Paraplegia, Polyethylene glycol, Polymer, Spinal cord injury, Surfactant",
author = "Laverty, {Peter H.} and Alenka Leskovar and Breur, {Gert J.} and Coates, {Joan R.} and Bergman, {Robert L.} and Widmer, {William R.} and Toombs, {James P.} and Scott Shapiro and Borgens, {Richard B.}",
year = "2004",
month = "12",
doi = "10.1089/neu.2004.21.1767",
language = "English",
volume = "21",
pages = "1767--1777",
journal = "Journal of Neurotrauma",
issn = "0897-7151",
publisher = "Mary Ann Liebert Inc.",
number = "12",

}

TY - JOUR

T1 - A preliminary study of intravenous surfactants in paraplegic dogs

T2 - Polymer therapy in canine clinical SCI

AU - Laverty, Peter H.

AU - Leskovar, Alenka

AU - Breur, Gert J.

AU - Coates, Joan R.

AU - Bergman, Robert L.

AU - Widmer, William R.

AU - Toombs, James P.

AU - Shapiro, Scott

AU - Borgens, Richard B.

PY - 2004/12

Y1 - 2004/12

N2 - Hydrophilic polymers, both surfactants and tri-block polymers, are known to seal defects in cell membranes. In previous experiments using laboratory animals, we have exploited this capability using polyethylene glycol (PEG) to repair spinal axons after severe, standardized spinal cord injury (SCI) in guinea pigs. Similar studies were conducted using a related co-polymer Poloxamer 188 (P 188). Here we carried out initial investigations of an intravenous application of PEG or P 188 (3500 Daltons, 30% w/w in saline; 2 mL/kg I.V. and 2 mL/kg body weight or 300 mL P 188 per kg, respectively) to neurologically complete cases of paraplegia in dogs. Our aim was to first determine if this is a clinically safe procedure in cases of severe naturally occurring SCI in dogs. Secondarily, we wanted to obtain preliminary evidence if this therapy could be of clinical benefit when compared to a larger number of similar, but historical, control cases. Strict entry criteria permitted recruitment of only neurologically complete paraplegic dogs into this study. Animals were treated by a combination of conventional and experimental techniques within ∼72 h of admission for spinal trauma secondary to acute, explosive disk herniation. Outcome measures consisted of measurements of voluntary ambulation, deep and superficial pain perception, conscious proprioception in hindlimbs, and evoked potentials (somatosensory evoked potentials [SSEP]). We determined that polymer injection is a safe adjunct to the conventional management of severe neurological injury in dogs. We did not observe any unacceptable clinical response to polymer injection; there were no deaths, nor any other problem arising from, or associated with, the procedures. Outcome measures over the 6-8-week trial were improved by polymer injection when compared to historical cases. This recovery was unexpectedly rapid compared to these comparator groups. The results of this pilot trial provides evidence consistent with the notion that the injection of inorganic polymers in acute neurotrauma may be a simple and useful intervention during the acute phase of the injury.

AB - Hydrophilic polymers, both surfactants and tri-block polymers, are known to seal defects in cell membranes. In previous experiments using laboratory animals, we have exploited this capability using polyethylene glycol (PEG) to repair spinal axons after severe, standardized spinal cord injury (SCI) in guinea pigs. Similar studies were conducted using a related co-polymer Poloxamer 188 (P 188). Here we carried out initial investigations of an intravenous application of PEG or P 188 (3500 Daltons, 30% w/w in saline; 2 mL/kg I.V. and 2 mL/kg body weight or 300 mL P 188 per kg, respectively) to neurologically complete cases of paraplegia in dogs. Our aim was to first determine if this is a clinically safe procedure in cases of severe naturally occurring SCI in dogs. Secondarily, we wanted to obtain preliminary evidence if this therapy could be of clinical benefit when compared to a larger number of similar, but historical, control cases. Strict entry criteria permitted recruitment of only neurologically complete paraplegic dogs into this study. Animals were treated by a combination of conventional and experimental techniques within ∼72 h of admission for spinal trauma secondary to acute, explosive disk herniation. Outcome measures consisted of measurements of voluntary ambulation, deep and superficial pain perception, conscious proprioception in hindlimbs, and evoked potentials (somatosensory evoked potentials [SSEP]). We determined that polymer injection is a safe adjunct to the conventional management of severe neurological injury in dogs. We did not observe any unacceptable clinical response to polymer injection; there were no deaths, nor any other problem arising from, or associated with, the procedures. Outcome measures over the 6-8-week trial were improved by polymer injection when compared to historical cases. This recovery was unexpectedly rapid compared to these comparator groups. The results of this pilot trial provides evidence consistent with the notion that the injection of inorganic polymers in acute neurotrauma may be a simple and useful intervention during the acute phase of the injury.

KW - Canine paraplegia

KW - P 188

KW - Paraplegia

KW - Polyethylene glycol

KW - Polymer

KW - Spinal cord injury

KW - Surfactant

UR - http://www.scopus.com/inward/record.url?scp=9744275280&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=9744275280&partnerID=8YFLogxK

U2 - 10.1089/neu.2004.21.1767

DO - 10.1089/neu.2004.21.1767

M3 - Article

VL - 21

SP - 1767

EP - 1777

JO - Journal of Neurotrauma

JF - Journal of Neurotrauma

SN - 0897-7151

IS - 12

ER -